Alkem Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Alkem Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 10.7% bzw. 9.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.6% betragen.

Wichtige Informationen

10.7%

Wachstumsrate der Gewinne

10.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.7%
Wachstumsrate der Einnahmen	9.5%
Zukünftige Eigenkapitalrendite	18.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Jan 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13

Recent updates

Alkem Laboratories Limited's (NSE:ALKEM) Shares May Have Run Too Fast Too Soon

Feb 01

Is Alkem Laboratories (NSE:ALKEM) A Risky Investment?

Jan 10

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 27

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Jul 13

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 27

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Jun 13

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

May 22

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13

Gewinn- und Umsatzwachstumsprognosen

NSEI:ALKEM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	161,549	27,528	19,790	23,269	18
3/31/2026	147,431	25,361	16,921	21,124	20
3/31/2025	133,325	22,342	15,906	23,794	20
9/30/2024	128,319	21,223	15,054	19,549	N/A
6/30/2024	127,317	20,542	N/A	N/A	N/A
3/31/2024	126,676	17,958	16,888	19,481	N/A
12/31/2023	126,344	15,732	N/A	N/A	N/A
9/30/2023	123,514	14,329	18,370	20,537	N/A
6/30/2023	119,906	11,433	N/A	N/A	N/A
3/31/2023	115,993	9,842	14,496	16,825	N/A
12/31/2022	111,805	10,208	N/A	N/A	N/A
9/30/2022	107,586	10,917	5,527	8,426	N/A
6/30/2022	104,792	13,051	N/A	N/A	N/A
3/31/2022	106,342	16,456	7,721	11,110	N/A
12/31/2021	103,425	17,780	N/A	N/A	N/A
9/30/2021	100,416	17,033	10,478	13,213	N/A
6/30/2021	96,044	16,311	N/A	N/A	N/A
3/31/2021	88,650	15,850	11,051	12,649	N/A
12/31/2020	87,218	15,338	N/A	N/A	N/A
9/30/2020	85,971	14,648	8,916	11,455	N/A
6/30/2020	84,984	13,636	N/A	N/A	N/A
3/31/2020	83,444	11,271	2,220	5,851	N/A
12/31/2019	81,484	11,057	N/A	N/A	N/A
9/30/2019	78,929	9,262	5,173	8,756	N/A
6/30/2019	75,478	8,098	N/A	N/A	N/A
3/31/2019	73,572	7,605	2,505	7,797	N/A
12/31/2018	70,157	6,602	N/A	N/A	N/A
9/30/2018	68,318	6,293	N/A	N/A	N/A
6/30/2018	67,788	6,955	N/A	N/A	N/A
3/31/2018	63,918	6,309	N/A	2,660	N/A
12/31/2017	60,044	7,009	N/A	N/A	N/A
9/30/2017	57,285	7,626	N/A	N/A	N/A
6/30/2017	55,019	7,248	N/A	N/A	N/A
3/31/2017	56,875	8,920	N/A	4,711	N/A
12/31/2016	56,933	7,732	N/A	N/A	N/A
9/30/2016	54,992	7,267	N/A	N/A	N/A
6/30/2016	52,419	7,108	N/A	N/A	N/A
3/31/2016	49,248	7,416	N/A	7,258	N/A
12/31/2015	47,975	8,189	N/A	N/A	N/A
9/30/2015	44,556	7,227	N/A	4,023	N/A
6/30/2015	40,459	5,781	N/A	N/A	N/A
3/31/2015	37,434	3,916	N/A	3,255	N/A
3/31/2014	31,191	4,353	N/A	2,900	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALKEMDas prognostizierte Gewinnwachstum (10.7% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: ALKEMDie Erträge des Unternehmens (10.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (18.1% pro Jahr).

Hohe Wachstumserträge: ALKEMDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: ALKEMDie Einnahmen des Unternehmens (9.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (11% pro Jahr).

Hohe Wachstumseinnahmen: ALKEMDie Einnahmen des Unternehmens (9.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ALKEMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.6%).

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/02/02 01:20
Aktienkurs zum Tagesende	2025/02/01 00:00
Gewinne	2024/09/30
Jährliche Einnahmen	2024/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

Alkem Laboratories Limited wird von 36 Analysten beobachtet. 20 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Nitin Bhasin	Ambit Capital
Prashant Nair	Ambit Capital
Shrikant Akolkar	Angel Broking Private Limited

Alkem Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Consensus EPS estimates increase by 10%

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 9.5% to ₹4,523

Recent updates

Alkem Laboratories Limited's (NSE:ALKEM) Shares May Have Run Too Fast Too Soon

Alkem Laboratories Limited to Report Q3, 2025 Results on Feb 07, 2025

Is Alkem Laboratories (NSE:ALKEM) A Risky Investment?

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Alkem Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Alkem Laboratories Limited Announces Retirement of Yogesh Kaushal as Senior Management Personnel

Alkem Laboratories Limited Approves Appointment of Rajeev Kher as an Independent Director

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Alkem Reportedly Joins $3 Billion Race for JB Chem as Torrent Pauses Talks

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

KKR, TPG Capital, Apax Partners and Other PE Firms Reportedly Eye Purchase of Sahajanand Medical Technologies

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Upcoming dividend of ₹5.00 per share

Full year 2024 earnings: EPS and revenues miss analyst expectations

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories Limited to Report Q1, 2025 Results on Aug 09, 2024

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Alkem Laboratories Limited Announces Change in Management

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Less than half of directors are independent

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Alkem Laboratories Limited, Annual General Meeting, Aug 30, 2024

Final dividend of ₹5.00 announced

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2024, Payable on and from 4 September, 2024

Full year 2024 earnings released: EPS: ₹150 (vs ₹82.31 in FY 2023)

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

Alkem Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Consensus EPS estimates increase by 10%

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 9.5% to ₹4,523

Third quarter 2024 earnings released: EPS: ₹49.76 (vs ₹38.03 in 3Q 2023)

Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023

Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy

Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position

Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position

Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director

Price target increased by 7.5% to ₹3,956

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Price target increased by 7.5% to ₹3,612

Upcoming dividend of ₹10.00 per share at 0.6% yield

Alkem Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2023, Payable on and from August 30, 2023

Alkem Laboratories Limited, Annual General Meeting, Aug 25, 2023

Alkem Laboratories Limited to Report Q4, 2023 Results on May 19, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited Declares Special Dividend for the Financial Year 2022-2023, Payable Be on and from 01 March, 2023

Alkem Laboratories Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on 1 March 2023

Alkem Laboratories Limited to Report Q3, 2023 Results on Feb 10, 2023

Eight Roads Ventures India Healthcare IV, L.P entered into a Shareholders’ Agreement to acquire a minority stake in Enzene Biosciences Ltd from Alkem Laboratories Limited (BSE:539523) for INR 1614.83 million.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

High number of new directors

U.S. Food and Drug Administration Conducts Pre-Approval Inspection At Alkem Laboratories Limited Manufacturing Facility Located At St. Louis, Usa